Logo image
Sign in
Back
Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]
Journal article   Open access

Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]

E. Y. Yu, J. M. Piulats, G. Gravis, P. C. C. Fong, T. Todenhöfer, B. Laguerre, J. A. Arranz, S. Oudard, C. Massard, J. Heinzelbecker, …
European urology, Vol.83(3)
2023
DOI: https://doi.org/10.1016/j.eururo.2022.11.025

Abstract

erratum
The authors regret that there was an error in the supplementary files – Table 6. The correct values for ‘Severe skin reaction’ are shown below, and also updated online accordingly. [Table presented]The authors would like to apologise for any inconvenience caused. © 2022
url
https://doi.org/10.1016/j.eururo.2022.11.025View
Published (Version of record) Open

Metrics

1 Record Views

Details